BR0211888A - Materiais e métodos para promoção de reparo de tecido nervoso - Google Patents

Materiais e métodos para promoção de reparo de tecido nervoso

Info

Publication number
BR0211888A
BR0211888A BR0211888-2A BR0211888A BR0211888A BR 0211888 A BR0211888 A BR 0211888A BR 0211888 A BR0211888 A BR 0211888A BR 0211888 A BR0211888 A BR 0211888A
Authority
BR
Brazil
Prior art keywords
methods
materials
tissue repair
nerve tissue
promoting nerve
Prior art date
Application number
BR0211888-2A
Other languages
English (en)
Portuguese (pt)
Inventor
David F Muir
Original Assignee
Univ Florida Res Foudantion In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida Res Foudantion In filed Critical Univ Florida Res Foudantion In
Publication of BR0211888A publication Critical patent/BR0211888A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3675—Nerve tissue, e.g. brain, spinal cord, nerves, dura mater
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/383—Nerve cells, e.g. dendritic cells, Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3878—Nerve tissue, brain, spinal cord, nerves, dura mater
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0211888-2A 2001-08-13 2002-08-13 Materiais e métodos para promoção de reparo de tecido nervoso BR0211888A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31187001P 2001-08-13 2001-08-13
PCT/US2002/025922 WO2003015612A2 (en) 2001-08-13 2002-08-13 Materials and methods to promote repair of nerve tissue

Publications (1)

Publication Number Publication Date
BR0211888A true BR0211888A (pt) 2004-08-24

Family

ID=23208862

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211888-2A BR0211888A (pt) 2001-08-13 2002-08-13 Materiais e métodos para promoção de reparo de tecido nervoso

Country Status (13)

Country Link
US (8) US6972168B2 (OSRAM)
EP (1) EP1425390B1 (OSRAM)
JP (1) JP4749667B2 (OSRAM)
KR (1) KR20040021697A (OSRAM)
CN (1) CN1553952A (OSRAM)
AT (1) ATE543509T1 (OSRAM)
BR (1) BR0211888A (OSRAM)
CA (1) CA2455827C (OSRAM)
ES (1) ES2378227T3 (OSRAM)
HU (1) HUP0500634A3 (OSRAM)
IL (1) IL160188A0 (OSRAM)
MX (1) MXPA04001334A (OSRAM)
WO (1) WO2003015612A2 (OSRAM)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670179B1 (en) * 2001-08-01 2003-12-30 University Of Kentucky Research Foundation Molecular functionalization of carbon nanotubes and use as substrates for neuronal growth
JP4749667B2 (ja) 2001-08-13 2011-08-17 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 神経組織の修復を促進するための材料および方法
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
EP1575548B1 (en) * 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US7163545B2 (en) * 2002-07-29 2007-01-16 Mayo Foundation For Medical Education And Research Spinal cord surgical implant
EP1530643B1 (en) * 2002-08-15 2011-05-04 Acorda Therapeutics, Inc. Chimeric protein
US7135027B2 (en) * 2002-10-04 2006-11-14 Baxter International, Inc. Devices and methods for mixing and extruding medically useful compositions
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA05012305A (es) * 2003-05-16 2006-04-18 Acorda Therapeutics Inc Composiciones y metodos para el tratamiento de lesiones del snc.
AU2004247025B8 (en) * 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
US7429375B2 (en) 2003-05-16 2008-09-30 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for the treatment of CNS
WO2005074655A2 (en) * 2004-01-30 2005-08-18 Emory University Materials and method for promotion of nerve regeneration
ES2411504T3 (es) * 2004-05-18 2013-07-05 Acorda Therapeutics, Inc. Métodos de purificación de condroitinasa y formulaciones estables de la misma
WO2005122734A2 (en) * 2004-06-14 2005-12-29 The Research Foundation Of State University Of New York Nanosphere/microsphere delivery system for the treatment of spinal cord injury
US20060041318A1 (en) * 2004-08-19 2006-02-23 Shannon Donald T Laminar skin-bone fixation transcutaneous implant and method for use thereof
WO2007038548A2 (en) * 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
US7599774B2 (en) * 2006-03-10 2009-10-06 Gm Global Technology Operations, Inc. Method and system for adaptively compensating closed-loop front-wheel steering control
KR101368742B1 (ko) * 2006-05-19 2014-02-28 세이가가쿠 고교 가부시키가이샤 뇌손상 개선제
EP2450442B1 (en) 2006-10-10 2017-07-19 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
WO2008149428A1 (ja) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
US9820747B2 (en) * 2008-04-04 2017-11-21 The Cleveland Clinic Foundation Use of epineural sheath grafts for neural regeneration and protection
EP2288376B1 (en) 2008-04-18 2016-01-13 Collplant Ltd. Methods of generating and using procollagen
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
US8758374B2 (en) 2010-09-15 2014-06-24 University Of Utah Research Foundation Method for connecting nerves via a side-to-side epineurial window using artificial conduits
WO2012177238A1 (en) * 2011-06-21 2012-12-27 Tamara Tennison System and method of repairing of neural networks
WO2013066619A1 (en) 2011-10-17 2013-05-10 University Of Utah Research Foundation Methods and devices for connecting nerves
US10842494B2 (en) 2011-10-17 2020-11-24 University Of Utah Research Foundation Methods and devices for connecting nerves
US20140341871A1 (en) 2011-12-30 2014-11-20 Paul R. Morris Regenerative tissue matrix
CN102716470B (zh) * 2012-06-28 2015-02-04 中国人民解放军第三军医大学第三附属医院 一种治疗周围神经损伤的药物组合物
WO2016145452A1 (en) * 2015-03-12 2016-09-15 Myoscience, Inc. Methods and systems for preventing neuroma formations
US11513039B2 (en) 2015-05-28 2022-11-29 Axogen Corporation Nerve culture system
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11156595B2 (en) * 2015-05-28 2021-10-26 Axogen Corporation Organotypic DRG-peripheral nerve culture system
CN105239137A (zh) * 2015-10-29 2016-01-13 无锡桥阳机械制造有限公司 一种电镀工艺
US10064938B2 (en) 2016-03-11 2018-09-04 University Of Wyoming Localized immunosuppression of allografts for peripheral nerve repair
WO2018111900A1 (en) * 2016-12-12 2018-06-21 The Regents Of The University Of California Biomimetic implants
WO2018127554A1 (en) * 2017-01-06 2018-07-12 Novahep Ab Methods of preparing bioengineered or bioprinted organ or tissue, and uses thereof
WO2019054407A1 (ja) * 2017-09-15 2019-03-21 東洋紡株式会社 神経保護材
WO2019099394A1 (en) * 2017-11-15 2019-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Systems and methods for reconstruction of nerve defects
CA3290756A1 (en) * 2018-04-12 2025-11-29 Axogen Corporation Tissue grafts with pre-made attachment points
WO2020014889A1 (zh) * 2018-07-18 2020-01-23 中山大学附属第一医院 四肢主干神经的仿生修复体模型的建立方法
CN108992709B (zh) * 2018-07-27 2021-05-14 山东省眼科研究所 一种脱细胞神经基质材料及其制备方法和应用
US11376219B2 (en) 2018-07-30 2022-07-05 University Of Wyoming Localized immunosuppression of allografts for peripheral nerve repair
US20200054467A1 (en) * 2018-08-20 2020-02-20 Zakary Llamo-Cohen Method for establishing an electrically conductive artificial nerve
IL283079B2 (en) * 2018-11-15 2024-01-01 Axogen Corp Materials and methods for nerve repair with animal-sourced nerve grafts
US11147558B2 (en) * 2018-11-15 2021-10-19 Axogen Corporation Materials and methods for nerve repair with animal-sourced grafts
CN109893680B (zh) * 2019-03-07 2021-10-08 宁波光远致信生物科技有限公司 一种修复纤维膜、修复套接管及其制备方法和用途
EP4682246A3 (en) 2019-12-30 2026-04-22 Renerva, LLC Extracellular matrix systems, devices, and methods of deployment
TW202233262A (zh) * 2020-10-22 2022-09-01 美商阿克松根股份有限公司 成束神經移植物、製造成束神經移植物之方法以及使用成束神經移植物之治療方法
WO2022256401A1 (en) * 2021-06-01 2022-12-08 Xenotherapeutics, Inc. Xenogeneic nerve transplants and methods
WO2023056008A2 (en) * 2021-09-30 2023-04-06 Renerva, Llc Nerve graft systems, devices, and methods
WO2023212531A1 (en) * 2022-04-27 2023-11-02 Board Of Regents, The University Of Texas System Polyethylene glycol-fusion in nerve repair
CN115944784B (zh) * 2023-01-04 2024-12-03 南通大学 一种细胞化纤维支架及其制备方法和应用
CN116570770B (zh) * 2023-07-12 2023-11-07 天新福（北京）医疗器材股份有限公司 一种双层冻干管状物及其制备方法与应用
AU2024363792A1 (en) * 2023-10-17 2026-04-23 Axogen Corporation Methods for analyzing a processed nerve graft

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US40112A (en) * 1863-09-29 Improvement in metallic cartridges
US77258A (en) * 1868-04-28 Improvement in weeding-hoe
US4778467A (en) * 1984-04-25 1988-10-18 The University Of Utah Prostheses and methods for promoting nerve regeneration and for inhibiting the formation of neuromas
US4696816A (en) * 1985-11-07 1987-09-29 Brown Mark D Method for treating intervertebral disc displacement with enzymes
US4933185A (en) * 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US4877029A (en) * 1987-03-30 1989-10-31 Brown University Research Foundation Semipermeable nerve guidance channels
US4870966A (en) * 1988-02-01 1989-10-03 American Cyanamid Company Bioabsorbable surgical device for treating nerve defects
AU6872691A (en) 1989-10-27 1991-05-31 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
AU6734190A (en) 1989-10-31 1991-05-31 La Jolla Cancer Research Foundation Inhibitor of laminin neurite promoting activity
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
US5173295A (en) * 1990-10-05 1992-12-22 Advance Biofactures Of Curacao, N.V. Method of enhancing the regeneration of injured nerves and adhesive pharamaceutical formulation therefor
US5231580A (en) 1991-04-01 1993-07-27 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Automated method and apparatus for determining characteristics of nerve fibers
US5496718A (en) 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
JP3419811B2 (ja) 1993-02-24 2003-06-23 マルハ株式会社 コンドロイチナーゼ遺伝子
EP1716864A1 (en) 1993-08-26 2006-11-02 Genetics Institute, LLC Neural regeneration using home bone morphogenetic proteins
US5916557A (en) 1993-11-12 1999-06-29 The Trustees Of Columbia University In The City Of New York Methods of repairing connective tissues
AU7949394A (en) * 1993-11-19 1995-06-06 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
US5716617A (en) * 1994-04-22 1998-02-10 American Cyanamid Company Compositions of proteus vulgaris chondroitinase I and chondroitinase II
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6093563A (en) * 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US6214987B1 (en) * 1994-09-02 2001-04-10 Andrew C. Hiatt Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides
US6057137A (en) * 1994-10-06 2000-05-02 Regents Of The University Of Minnesota Tissue-equivalent rods containing aligned collagen fibrils and schwann cells
US5487756A (en) * 1994-12-23 1996-01-30 Simon Fraser University Implantable cuff having improved closure
CA2208780C (en) 1995-01-30 2010-03-30 Peter Truog Antitumor and anticholesterol preparations comprising lipoteichoic acid lta-t of streptococcus sp dsm 8747
US6033660A (en) * 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US6231608B1 (en) * 1995-06-07 2001-05-15 Crosscart, Inc. Aldehyde and glycosidase-treated soft and bone tissue xenografts
JP3093974B2 (ja) 1995-06-27 2000-10-03 住友ベークライト株式会社 神経細胞用培養液、その製造方法及びこれを用いる神経細胞の培養方法
US6313265B1 (en) * 1995-07-24 2001-11-06 The Scripps Research Institute Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
DE19530556C1 (de) 1995-07-28 1996-09-05 Will Prof Dr Minuth Verfahren zum Kultivieren von Zellen des menschlichen oder tierischen Körpers
US5866120A (en) * 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
SE9602879D0 (sv) * 1996-07-26 1996-07-26 Henrich Cheng Medical device
WO1998046258A2 (en) * 1997-04-11 1998-10-22 Beth Israel Deaconess Medical Center, Inc. Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions
EP0875253B1 (en) 1997-05-02 2005-04-06 Seikagaku Corporation Chondroitinase compositions
US6448076B2 (en) 1998-09-15 2002-09-10 The Regents Of The University Of Michigan Method for chemically acellularizing a biological tissue sample
DE69933686T2 (de) * 1998-10-06 2007-08-23 Rush University Medical Center, Chicago Zusammensetzung zur verwendung in der chemonukleolyse
US20030068815A1 (en) 1999-02-11 2003-04-10 Stone Kevin R. Sterilized xenograft tissue
US6267786B1 (en) 1999-02-11 2001-07-31 Crosscart, Inc. Proteoglycan-reduced soft tissue xenografts
AU783222B2 (en) 1999-11-17 2005-10-06 Biomarin Pharmaceutical Inc. Attenuation of tumor growth, metastasis and angiogenesis by use of chondroitin sulfate degrading enzymes
JP2004504262A (ja) 1999-12-02 2004-02-12 アイベックス　テクノロジーズ，　インコーポレイテッド 線維芽細胞の増殖の弱毒化
WO2001053474A2 (en) 2000-01-21 2001-07-26 Ibex Pharmaceuticals, Inc. Flavobacterium heparinum expression system
WO2002009756A1 (en) 2000-07-28 2002-02-07 Sumitomo Pharmaceuticals Company, Limited Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient
JP4749667B2 (ja) 2001-08-13 2011-08-17 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 神経組織の修復を促進するための材料および方法
WO2005118609A2 (en) 2004-05-26 2005-12-15 California Institute Of Technology Small molecule stimulators of neuronal growth

Also Published As

Publication number Publication date
KR20040021697A (ko) 2004-03-10
ATE543509T1 (de) 2012-02-15
EP1425390A4 (en) 2009-03-04
WO2003015612A2 (en) 2003-02-27
WO2003015612A9 (en) 2004-04-29
HUP0500634A3 (en) 2006-03-28
MXPA04001334A (es) 2004-05-05
WO2003015612A3 (en) 2004-03-25
JP4749667B2 (ja) 2011-08-17
US20030077258A1 (en) 2003-04-24
CA2455827C (en) 2015-06-09
CN1553952A (zh) 2004-12-08
US20160339148A1 (en) 2016-11-24
US20110082482A1 (en) 2011-04-07
US20080299536A1 (en) 2008-12-04
US8986733B2 (en) 2015-03-24
US20030040112A1 (en) 2003-02-27
US20040180434A1 (en) 2004-09-16
EP1425390A2 (en) 2004-06-09
ES2378227T3 (es) 2012-04-10
US9402868B2 (en) 2016-08-02
HUP0500634A2 (hu) 2005-09-28
IL160188A0 (en) 2004-07-25
US20130337549A1 (en) 2013-12-19
JP2005500375A (ja) 2005-01-06
US10441681B2 (en) 2019-10-15
US20030072749A1 (en) 2003-04-17
CA2455827A1 (en) 2003-02-27
EP1425390B1 (en) 2012-02-01
US7732200B2 (en) 2010-06-08
US6972168B2 (en) 2005-12-06
US7851447B2 (en) 2010-12-14

Similar Documents

Publication Publication Date Title
MXPA04001334A (es) Materiales y metodos para promover la reparacion de tejido nervioso.
DE60330181D1 (de) Actriib-fusionspolypeptide und verwendungen dafür
BR0306846A (pt) Produto substituto do sangue, composição útil como um substituto do sangue, método para fazer um produto substituto do sangue, e, método de uso de um produto substituto do sangue para fornecer oxigênio a um tecido
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
BR0214838A (pt) Composição para promoção de crescimento ósseo e manutenção da saúde óssea
WO2004019884A3 (en) Agents and methods for enhancing bone formation
AU2003275958A1 (en) Muteins of tear lipocalin
AU2003225800A1 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
EA200300862A1 (ru) Связывание эндотоксина под действием лактобактерий и бифидобактерий
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
BR0100558A (pt) Composições e métodos para tratar a osteoporose
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BRPI0408061A (pt) tratamento médico utilizando um agonista de receptores seletivos de ep 2
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
EP2067472A8 (en) Compositions and methods for the diagnosis and treatment of tumor
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
PT2009025E (pt) Método de inibição da actividade dos osteoclastos
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
DE68924006D1 (de) Pharmazeutische Zusammensetzungen mit Eierschalenbestandteilen und ihre Herstellung und Verwendung.
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.